IMS Health to Issue Second-Quarter 2013 Financial Results on July 30, Conference Call for Note Holders Scheduled for July 31
DANBURY, Conn.--(BUSINESS WIRE)-- IMS Health plans to post for note holders its second-quarter 2013 financial results on Tuesday, July 30, 2013. The company will conduct a conference call for IMS Health's note holders to review these results at 5:30 p.m. ET on Wednesday, July 31, 2013. To obtain additional details for accessing the company's results and joining the conference call, note holders should e-mail firstname.lastname@example.org.
IMS Health is a leading worldwide provider of information, technology and services dedicated to making healthcare perform better. With a global technology infrastructure and unique combination of real-world evidence, advanced analytics and proprietary software platforms, IMS Health connects knowledge across all aspects of healthcare to help clients improve patient outcomes and operate more efficiently. The company's expert resources draw on data from nearly 100,000 suppliers, and on insights from more than 40 billion healthcare transactions processed annually, to serve more than 5,000 healthcare clients globally. Customers include pharmaceutical, medical device and consumer health manufacturers and distributors, providers, payers, government agencies, policymakers, researchers and the financial community. Additional information is available at www.imshealth.com.
Tammy Tobin, Investor Relations, 203-448-4663
KEYWORDS: United States North America Connecticut
The article IMS Health to Issue Second-Quarter 2013 Financial Results on July 30, Conference Call for Note Holders Scheduled for July 31 originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.